SEC Company Response from Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Apr 10, 2019
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: April 10, 2019 · CIK: 0001006281 · Accession: 0001144204-19-018975
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230604
Letter
VIA EDGAR Office of Healthcare and Insurance Division of Corporate Finance Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed March 29, 2019 File No. 333-230604
Dear Mr. McCann:
We refer to the registration statement on Form S-3 (File No. 333-230604) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:05 p.m. (Eastern time) on April 12, 2019 or as soon as practicable thereafter.
We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or YossiM@protalix.com, or the Company’s counsel, Anna T. Pinedo of Mayer Brown LLP at +1 (212) 506-2275 or apinedo@mayerbrown.com.
Sincerely,
/s/ Yossi Maimon
Show Raw Text
CORRESP 1 filename1.htm April 10, 2019 VIA EDGAR Joseph McCann Office of Healthcare and Insurance U.S. Securities and Exchange Commission Division of Corporate Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed March 29, 2019 File No. 333-230604 Dear Mr. McCann: We refer to the registration statement on Form S-3 (File No. 333-230604) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:05 p.m. (Eastern time) on April 12, 2019 or as soon as practicable thereafter. We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or YossiM@protalix.com, or the Company’s counsel, Anna T. Pinedo of Mayer Brown LLP at +1 (212) 506-2275 or apinedo@mayerbrown.com. Sincerely, /s/ Yossi Maimon Yossi Maimon Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. cc: Moshe Manor Protalix BioTherapeutics, Inc. Anna T. Pinedo Mayer Brown LLP 2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel Tel: 972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com